



Turning ideas into assets in life sciences

27/09/2023

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE



AGENDA

14:30 - 14:35 : Welcome
Caroline Ven, CEO of pharma.be

14:35 - 14:45 : pharma.be on IP as an innovation enabler
Charlotte Weyne, Senior Legal Counsel & European Policy Advisor at pharma.be

14:45 - 14:55 : The IP framework by the Intellectual property administration
Gunther Aelbrecht, Head IP Office at FOD Economie / SPF Economie / FPS Economy

Second part moderated by **Isabelle François** - Director Innovation at Medvia

15:00-15:20 : Insights from the academic sector
Prof. Mohamed Lamkanfi, Full Professor of Medical Immunology at Ghent University

Patrick Chaltin, Managing Director at Centre for Drug Design and Discovery (CD3)

15:20-16:05 : Break



AGENDA

16:05 - 16:30 : Perspectives about Tech Transfer, Venture Capitalist and fund participation, and harnessing competitiveness

Jo Bury, Managing Director VIB

Sylvie Ponchaut, Managing director BIOWIN, health competitiveness cluster of Wallonia

Philippe De Backer, Senior Partner at Newton Biocapital

16:30 - 16:50 : Experiences from diverse players in the biopharma industry

Tim Van Hauwermeiren, Chief Executive Officer at Argenx

Antoon Loomans, Senior Vice President & General Counsel Vaccines, Corporate and Global Health at GSK Vaccines

16:50 - 17H00 : Keynote speech

Prof. Reinhilde Veugelers, Professor of Managerial Economics, Strategy and Innovation at KULeuven

17:00-18:00 : Networking drink



Welcome

Caroline Ven, CEO of pharma.be

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE



pharma.be on IP as an innovation enabler

Charlotte Weyne

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE



The IP framework by the Intellectual property administration

Gunther Aelbrecht

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

Turning ideas into assets in life sciences – 27/09/2023

The IP framework

Gunther Aelbrecht, IP Office, FPS Economy



1) What are Intellectual Property Rights?

2) Why do they exist?

**3) Focus on life sciences: patents & SPC's
(Supplementary Protection Certificate)**

4) Belgian Landscape IP and life sciences



1) What are Intellectual Property Rights?

- a set of exclusive rights that relate to "products of the mind"
- Categories:

| INDUSTRIAL PROPERTY | COPYRIGHT AND RELATED RIGHTS |
|--------------------------|---|
| Patents | Copyright |
| Trademarks | Related rights |
| Designs | Database law |
| Plant breeders' rights | Semiconductor topographies (chips- design) |
| Geographical indications | |
| Trade secrets | |



2) Why do IPRs exist?

- **Compensate:** enable people to earn recognition or financial benefit from what they invent or create;
- **Stimulate** innovation and creation by striking the right balance between the interests of innovators and the wider public interest;



3) Focus on life sciences: patents & SPC's (Supplementary Protection Certificate)

Patent: is an exclusive right granted for an invention
(a product or a process that provides, in general, a new way of doing something, or offers a new technical solution to a problem)




Conditions:

- New: does not exist prior to patent application
- Inventive: not obvious to the skilled person
- Industrially applicable: useful in some practical sense, not abstract
- Lawful (e.g. interdiction cloning human bodies)

Duration: maximum 20 years from application



Procedure (EPO – EP and UP)



Supplementary Protection Certificate

- SPC: extends the duration of protection of the medicinal product by the patent. Same exclusive rights as the basic patent
- Reason: compensate for time that it takes to obtain market authorization for a patented drug

Duration: maximum 5 years from end patent protection

Procedure: currently national procedures – 27.04.2023 EUCOM proposal for Unitary SPC



4) Belgian Landscape IP and life sciences

European Patent applications by Belgian applicants for pharmaceuticals and cosmetics (**A61K/IC**)

2015: 219

2016: 204

2017: 199

2018: 207

2019: 207


2020: 219

2021: 259

2022: 194




SPC Demands



SPC Grants

■ Delivr. ■ Refu.



Thank you for your attention





Insights from the academic sector

Prof. Mohamed Lamkanfi, & Patrick Chaltin

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE



Break

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE



Perspectives about Tech Transfer, Venture Capitalist and fund participation, and harnessing competitiveness

Jo Bury, Sylvie Ponchaut & Philippe De Backer

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE



Experiences from diverse players in the biopharma industry

Tim Van Hauwermeiren & Antoon Loomans

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE



Keynote speech

Prof. Reinhilde Veugelers

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE



Networking drink

Thank you!

pharma.be

ASSOCIATION GÉNÉRALE DE L'INDUSTRIE DU MÉDICAMENT
ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

Discover our digital publication on Intellectual Property



pharma.be

**Association générale de
l'industrie du médicament
asbl**

Chaussée de La Hulpe 166
1170 Bruxelles

Numéro d'entreprise
0407.622.902

**Algemene vereniging van de
Geneesmiddelenindustrie
vzw**

Terhulpesteenweg 166
1170 Brussel

Ondernemingsnummer
0407.622.902

T 02 661 91 11

www.pharma.be | info@pharma.be
RPR Brussel